Program
Ezetimibe
Also written as “ezetimibe”, “ezetimibe (+) simvastatin” and “MK0653, ezetimibe”.
Its studies are mostly in Hypercholesterolemia · Hypertension · Hyperlipidemias · Lipid Metabolism, Inborn Errors · Atherosclerosis, led by 16 companies.
Drug pageEzetimibe: every studyMany companies study it; this page follows only the 97 they lead. All 208 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 710 open or running | phase 4since Sep 7, 2005 | Sep 23, 2004 | none ahead |
| Daiichi Sankyoits history only | 61 open or running | phase 4since Sep 9, 2005 | Sep 9, 2005 | Jun 1, 2028phase 3 · NCT07474649 |
| Yuhanits history only | 40 open or running | phase 4since Jul 12, 2017 | Jul 12, 2017 | none ahead |
| IlDong Pharmaceuticalits history only | 20 open or running | phase 3since Sep 25, 2014 | Sep 25, 2014 | none ahead |
| JW Pharmaceuticalits history only | 21 open or running | phase 4since Feb 18, 2026 | Oct 6, 2020 | none ahead |
| Novartisits history only | 20 open or running | phase 4since Oct 10, 2006 | Sep 12, 2005 | none ahead |
| Celltrionits history only | 10 open or running | phase 3since Apr 27, 2026 | Apr 27, 2026 | none ahead |
| Daewon Pharmaceuticalits history only | 10 open or running | phase 3since Jul 24, 2023 | Jul 24, 2023 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Mar 22, 2012 | Mar 22, 2012 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 3since Dec 2, 2020 | Dec 2, 2020 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 1since Apr 29, 2014 | Apr 29, 2014 | none ahead |
| HK inno.Nits history only | 10 open or running | phase 4since Nov 20, 2018 | Nov 20, 2018 | none ahead |
| hyundai-pharmits history only | 11 open or running | phase 3since Oct 15, 2024 | Oct 15, 2024 | none ahead |
| Merckits history only | 10 open or running | phase 4since Sep 16, 2008 | Sep 16, 2008 | none ahead |
| NVP Healthcareits history only | 10 open or running | phase 1since Nov 9, 2014 | Nov 9, 2014 | none ahead |
| Shin Poong Pharmaceuticalits history only | 10 open or running | phase 3since Aug 18, 2017 | Aug 18, 2017 | none ahead |
Also a collaborator on its studies: Pharma Medica Research, Regeneron Pharmaceuticals, Merck Frosst Canada, Linical Korea and Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 40 studies since Mar 31, 2008.
- Nov 20, 2018HK inno.N’s first study: phase 4 study in HypertensionNew to HK inno.NHK inno.N · NCT03847506 · 127 enrolled · Korea, Republic of
- Mar 6, 20195 phase 3 studiesOrganon · NCT03884452, NCT03867110, NCT03882996 and 2 more
- Mar 11, 2019Phase 3 study in HypercholesterolemiaYuhan · NCT03872232 · 180 enrolled · Korea, Republic of
- Aug 8, 2019Phase 4 study in Acute Coronary SyndromeYuhan · NCT04056169 · 50 enrolled · Korea, Republic of
- Nov 7, 2019Phase 3 study in HypercholesterolemiaYuhan · NCT04158076 · 131 enrolled · Korea, Republic of
- Oct 6, 2020JW Pharmaceutical’s first study: phase 3 study in Primary HypercholesterolemiaNew to JW PharmaceuticalJW Pharmaceutical · NCT04584736 · 283 enrolled · Korea, Republic of
- Dec 2, 2020Hanlim Pharm.’s first study: phase 3 study in HypertensionNew to Hanlim Pharm.Hanlim Pharm. · NCT04659070 · 156 enrolled · Korea, Republic of
- Jul 24, 2023Daewon Pharmaceutical’s first study: phase 3 study in HypercholesterolemiaNew to Daewon PharmaceuticalDaewon Pharmaceutical · NCT05970679 · 252 enrolled · Korea, Republic of
- Oct 15, 2024hyundai-pharm’s first study: phase 3 study in HypertensionNew to hyundai-pharmhyundai-pharm · NCT06646354 · 125 planned · Korea, Republic of
- Sep 11, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07182383, NCT07201545
- Nov 14, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07235189, NCT07268625
- Feb 18, 2026Phase 4 study in HypercholesterolemiaJW Pharmaceutical · NCT07442630 · 88 enrolled · South Korea
- Mar 11, 2026Phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649 · 103 planned · Germany, Italy, Spain
- Apr 27, 2026Celltrion’s first study: phase 3 study in HypertensionNew to CelltrionCelltrion · NCT07564726 · 163 enrolled · South Korea
Ahead
- Jun 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649
TargetBeta
“Niemann-Pick C1-like protein 1 inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 97 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07564726Hypertension · South Korea | 3 | Completed | Celltrion | Feb 13, 2024 | 163 |
| NCT07474649Coronary Artery Disease · Germany, Italy, Spain | 3 | Recruiting | Daiichi Sankyo | Jun 1, 2028 | 103 |
| NCT07442630Hypercholesterolemia · South Korea | 4 | Active, not recruiting | JW Pharmaceutical | Jan 22, 2026 | 88 |
| NCT07268625Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Feb 24, 2026 | 58 |
| NCT07235189Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Jan 28, 2026 | 58 |
| NCT07201545Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Dec 10, 2025 | 58 |
| NCT07182383Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Nov 24, 2025 | 58 |
| NCT06646354Hypertension · Korea, Republic of | 3 | By invitation | hyundai-pharm | May 19, 2025 | 125 |
| NCT05970679Hypercholesterolemia · Korea, Republic of | 3 | Completed | Daewon Pharmaceutical | Apr 13, 2023 | 252 |
| NCT04659070Hypertension · Korea, Republic of | 3 | UNKNOWN | Hanlim Pharm. | May 19, 2022 | 156 |
| NCT04584736Primary Hypercholesterolemia · Korea, Republic of | 3 | Completed | JW Pharmaceutical | Jul 16, 2020 | 283 |
| NCT04158076Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Jan 14, 2021 | 131 |
| NCT04056169Acute Coronary Syndrome · Korea, Republic of | 4 | Completed | Yuhan | Jul 23, 2019 | 50 |
| NCT03882996Hypercholesterolemia | 3 | Completed | Organon | Feb 4, 2003 | 432 |
| NCT03882905Primary Hypercholesterolemia | 3 | Completed | Organon | Jul 27, 2001 | 769 |
| NCT03882892Hypercholesterolemia | 3 | Completed | Organon | Aug 8, 2002 | 400 |
| NCT03872232Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Aug 12, 2020 | 180 |
| NCT03884452Hyperlipoproteinemia Type II | 3 | Completed | Organon | May 24, 2001 | 50 |
| NCT03867110Hypercholesterolemia | 3 | Completed | Organon | Jul 27, 2001 | 628 |
| NCT03847506Hypertension · Korea, Republic of | 4 | Completed | HK inno.N | Dec 2, 2020 | 127 |
| NCT03288038Hypercholesterolemia · Korea, Republic of | 3 | Completed | Shin Poong Pharmaceutical | Nov 19, 2015 | 382 |
| NCT03217409Diabetes Mellitus · Korea, Republic of | 4 | Completed | Yuhan | Apr 3, 2019 | 85 |
| NCT02748057Hypercholesterolemia | 3 | Completed | Organon | Dec 11, 2017 | 135 |
| NCT02749994Hypercholesterolemia · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Feb 2017 | 396 |
| NCT02741245Hypercholesterolemia | 3 | Completed | Organon | Jan 18, 2017 | 321 |
| NCT02550288Hypercholesterolemia | 3 | Completed | Organon | May 30, 2016 | 309 |
| NCT02460159Hypercholesterolemia | 3 | Completed | Organon | Dec 22, 2016 | 135 |
| NCT02289430Healthy | 1 | Completed | NVP Healthcare | Feb 2015 | 59 |
| NCT02251847Hypercholesterolemia · Korea, Republic of | 3 | UNKNOWN | IlDong Pharmaceutical | Jul 2015 | 400 |
| NCT02127320Healthy · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Sep 2014 | 24 |
| NCT01611883Hypercholesterolemia | 4 | Completed | Organon | Jan 16, 2014 | 152 |
| NCT01597700Hypercholesterolemia · India | 1 | Completed | GlaxoSmithKline | Jan 30, 2012 | 52 |
| NCT01370603Hypercholesterolemia | 3 | Completed | Organon | May 2012 | 328 |
| NCT01370590Hypercholesterolemia | 3 | Completed | Organon | Apr 2012 | 406 |
| NCT01154036Hypercholesterolemia | 3 | Completed | Organon | Sep 2012 | 1,547 |
| NCT00871351Primary Hypercholesterolemia | 4 | Completed | Organon | May 1, 2010 | 125 |
| NCT00867165Primary Hypercholesterolemia | 3 | Completed | Organon | Apr 13, 2012 | 138 |
| NCT00862251Cardiovascular Diseases | 3 | Completed | Organon | Mar 2011 | 808 |
| NCT00753883Hyperlipidemias | 4 | Completed | Merck | May 2008 | 40 |
| NCT00654628Hypercholesterolemia | 4 | Completed | Organon | Jul 1, 2009 | 173 |
| NCT00654095Hypercholesterolemia | 3 | Completed | Organon | Jun 1, 2009 | 146 |
| NCT00653835Hypercholesterolemia | 4 | Completed | Organon | Aug 1, 2004 | 153 |
| NCT00653796Hypercholesterolemia | 4 | Completed | Organon | Aug 1, 2004 | 148 |
| NCT00653523Hypercholesterolemia | 3 | Completed | Organon | Jun 1, 2009 | 151 |
| NCT00653276Cholesterol | 1 | Completed | Organon | Jan 2004 | 13 |
| NCT00652847Hypercholesterolemia | 4 | Completed | Organon | May 2007 | 1,140 |
| NCT00652717Cardiovascular Diseases | 4 | Completed | Organon | Feb 15, 2005 | 280 |
| NCT00653913Hypercholesterolemia | 1 | Completed | Organon | Sep 2004 | 18 |
| NCT00652444Hypercholesterolemia | 4 | Completed | Organon | Aug 2004 | 120 |
| NCT00652327Hypercholesterolemia | 4 | Completed | Organon | Jul 2007 | 83 |
| NCT00652301Cholesterol | 3 | Completed | Organon | Apr 2004 | 40 |
| NCT00651963Lipid Metabolism Disorders | 4 | Completed | Organon | Mar 2005 | 80 |
| NCT00651560Hyperlipidemias | 3 | Completed | Organon | Dec 23, 2005 | 167 |
| NCT00651404Hypercholesterolemia | 3 | Completed | Organon | Dec 2004 | 137 |
| NCT00651391Hypercholesterolemia | 3 | Terminated | Organon | Sep 1, 2004 | 28 |
| NCT00651274Atherosclerosis | 4 | Completed | Organon | Aug 1, 2004 | 144 |
| NCT00651144Hypercholesterolemia | 1 | Completed | Organon | May 2003 | 40 |
| NCT00651014Hypercholesterolemia | 4 | Terminated | Organon | Jun 2006 | 82 |
| NCT00650819Hypercholesterolemia | 3 | Completed | Organon | Feb 1, 2005 | 240 |
| NCT00650689Hypercholesterolemia | 3 | Completed | Organon | Dec 2004 | 122 |
How it is read
Names in the registry
- “Ezetimibe”, 31 entries
- “ezetimibe”, 11 entries
- “ezetimibe (+) simvastatin”, 10 entries
- “MK0653, ezetimibe”, 7 entries
- “CKD-828, D097, D337”, 6 entries
Codes read as this program: MK0653.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 73 studies
- Hypertension, 9 studies
- Hyperlipidemias, 7 studies
- Lipid Metabolism, Inborn Errors, 3 studies
- Atherosclerosis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.